At present, immunotherapy has always been a potential part of comprehensive therapy for gastric cancer through blocking immune checkpoints, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death-1 (PD-1), and its ligand (PD-L1) [41]. The gene discussed is PDCD1; the disease is gastric cancer.